更昔洛韦治疗小儿传染性单核细胞增多症疗效观察

The Clinica Analysis of Ganciclovirum for Children Infectious Mononucleosis Treatment

目的:观察更昔洛韦治疗小儿传染性单核细胞增多症(IM)的临床疗效和安全性。方法:将确诊为传染性单核细胞增多症的28例患儿随机分为更昔洛韦治疗组15例和利巴韦林对照组13例,进行比较研究。结果:更昔洛韦治疗组热程、咽峡炎、淋巴结、肝脾肿大时间明显少于对照组(P<0.01和0.001),有显著性差异;治疗组总有效率93.3%,明显高于对照组总有效率61.5%(P<0.01)。短期使用更昔洛韦剂量控制在8～10mg/(kg.d),未见明显不良反应发生。结论:更昔洛韦治疗小儿传染性单核细胞增多症安全、有效,值得临床推广应用。

Objective：To observe the clinica effects and safety of ganciclovirunm for children infectious momomucleosis.Methods：28 cases diagnosed children were divided into ganciclovirum group（n=15）and virazole group（n=13）randomLy.The two groups accepted gancilovirum and virazole trenment respectively.The clinical effects and side effects were compared.Results：The fever period,the time of lymph node,liver,spleen enlargement,pharyngitis of ganciclovirum group were shorter than those of virazole group（P0.01和0.001）.The difference was significant.The total effective rate was 93.3% in ganciclovirum group and 61.5% in the virazole group（P0.01）.No obvious side effect was observed during ganciclovirum treament period.Conclusion：Ganciclovirum is more effective and safe for children infectious momomucleosis.